European Biosolutions Coalition’s Post

On paper this sounds great! In reality, we are stifled by all kinds of regulations starting with GDPR and so forth. It's illusive Europe will be independently able to catch up any time soon. Our chance lies in collaborations with other nations including the US and the poorly apprechiated China with excellent opportunities to generate and use clinical and other data for the next generation drug discovery and diagnostics revolution that may eventually bring us Precision Medicine https://lnkd.in/e8eMgBjD Off note, did you know Hainan wellcomes healthtech companies with advanced approval programs and one-stop-shop resources for drug development?

Why shouldn’t 2025 be the year of biosolutions? 🌍🤔 We know by now that 2025 will be a crucial time for biosolutions, and in fact, at the Coalition, we believe that 2025 can be the year of biosolutions. Let’s take a look at what the year has in store. While you can be sure that we’re bringing you much more information shortly, we’re already looking forward to our European High-Level Conference on Biosolutions on the 13th of May. 📅✨ Our preparations are well underway, and we can’t wait to show you everything we’ve got going on. It’ll be the biosolutions event of the calendar year! 🌱 In the meantime, the sector is facing important developments. With the new Commission in place, 2025 will also be the year the European Biotech Act will be presented. 📜 This was first promised in President von der Leyen’s Political Guidelines last year, where the Commission committed themselves to make the most of the biotech revolution. And bringing biosolutions faster to the European market will be crucial to using the full potential this revolution has to offer. 🚀 Implementing a bold Biotech Act is of utmost importance, but it doesn’t stand alone. The Commission is currently revising the Bioeconomy Strategy and conducting studies that will support the broader biotech sector, including bio-based products and biosolutions. Overall, 2025 can be an absolutely crucial year for advancing biosolutions and their unfathomably large potential. But there is still much left to achieve. So, for 2025, we remain hopeful that biosolutions can be advanced in Europe. Yet we also recommit ourselves to our efforts, as the work is far from done. Let’s make 2025 the year of biosolutions! 🤝🌿

🧬 This week, EuropaBio - the European Association for Bioindustries held its Council and Board meetings — an inspiring moment to reflect on 𝐛𝐢𝐨𝐭𝐞𝐜𝐡'𝐬 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐫𝐞𝐜𝐨𝐠𝐧𝐢𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐯𝐢𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐲 in the EU and to chart the path forward for the #biotech 𝐚𝐠𝐞𝐧𝐝𝐚 𝐭𝐨 𝟐𝟎𝟐𝟗. 🧬 Together with our National Associations and Healthcare Councils, we: 🔵 Reviewed progress on the Pharma Package negotiations and critical actions from national biotech associations — ensuring it works for biotech. 🔵 Aligned on ambitions for the EU #BiotechAct and other transformative initiatives like the Life Sciences Strategy and the EU Innovation Act. The big picture? Biotech is now firmly anchored into the EU’s strategic priorities. It’s recognised as a 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 — essential for Europe’s future competitiveness and prosperity. The March 2024 Communication on Boosting Biotech & Biomanufacturing in the EU gives us a 𝐜𝐥𝐞𝐚𝐫 𝐫𝐨𝐚𝐝𝐦𝐚𝐩 to shape this industry for future generations. But the work doesn’t stop here. Fo 2024-2029, we face a 𝐟𝐮𝐥𝐥 𝐩𝐨𝐥𝐢𝐜𝐲 𝐚𝐠𝐞𝐧𝐝𝐚 with over 20 relevant initiatives. Each one is a chance to strengthen our biotech ecosystem and deliver on the EU’s transitions, competitiveness, and prosperity. It’s a challenge I’m excited to take on — together with our members, colleagues, and the wider biotech community. What’s your vision for Europe’s biotech future? Let’s keep shaping it, together.

In the European Biosolutions Coalition we would like to congratulate Mrs Ursula von der Leyen on her reelection as president of the European Commission yesterday. We are very happy with your ambitions for biosolutions in your political guidelines 2024-2029 and with your words on how you want Europe to make the most of the biotech revolution. We could not agree more! Europe has great opportunities to create a true biorevolution speeding up the green transition and enhance competitiveness and resilience at the same time 🌱💪 For that we need the EU Biotech Act 🙌🇪🇺 #biosolutions #greentransition #competitiveness #resilience

👏 Great news! There is strong support from EU member states to a broad scope for the proposed EU Biotech Act. Today, the Competitiveness Council (COMPET) held a council meeting with the ministers responsible for internal market and industry. Their agenda was multifaceted, with the future of European competitiveness and the conclusions of the Draghi report on the agenda, and including an exchange of views on better regulation in the EU. In particular though, the agenda of any other business was of interest today. Not only did the Finnish delegation inform on the next steps for a European bioeconomy, the Danish delegation introduced “Reaping the full benefits of the biotech revolution.” These proposals received backing from Germany, Latvia, Lithuania, France, Sweden, Portugal, Spain, Estonia, Belgium, the Netherlands and Ireland. The countries supported a wider scope for the upcoming Biotech Act, one that also embraces sectors such as marine biotechnology, agrifood and general industrial processes, alongside the health sector. The European Commission welcomed the proposals and underlined the bio-based industry’s importance for Europe’s competitiveness and sustainability, and the need to streamline market access and ensure a level playing field. Currently, Europe, and specifically biotechnological sectors, suffer from a multitude of regulatory barriers – these affect many sectors, and must also be tackled across many sectors. Otherwise, the risk of European companies that were born here choosing to grow elsewhere in rival markets becomes very real. We support this position. We cannot limit the Biotech Act to be focused on health only. While this is also important, a broader Act is necessary. Let’s push for a bold Biotech Act. Let’s push for biosolutions 🌱 Are you curious to learn about the many different products and applications take a look at the Coalition’s European case catalogue: https://lnkd.in/dH6GtTET #biosolutions #competitiveness #sustainability Sofie Carsten Nielsen Marit Hvithamar Rystrøm

🎥 Missed the event? Watch the highlights! Held in cooperation with FTI Consulting EU, the launch of the "The Economic Lens: Understanding What Makes the EU Attractive for Life Sciences" report brought together top minds in investment, policy, and life sciences to discuss the EU’s strengths, challenges, and the future of the #PharmaceuticalSector. 💡 In case you couldn’t join, we’ve got you covered! Watch the short recap video of the insightful discussion. 💼 Topics: 🔹 How does Europe compare with the US, when attracting #investment in life sciences – what are Europe’s strengths & weaknesses? 🔹 How to improve #EUCompetitiveness for the pharmaceutical sector, also reflecting on the Draghi and Letta reports, the proposed #PharmaPackage and the future #EUAgenda? 🔹 How can the EU build a thriving pharmaceutical ecosystem, what are the challenges ahead, in particular for small and mid-sized companies? ✨ Highlights include: 💬 Keynote: MEP Stine Bosse, Vice-Chair, Subcommittee on Public Health (#SANT), European Parliament 🗣️ Insights from top industry leaders, policymakers, and investors including: 🔸 Florian Schmidt (DG SANTE - European Commission), 🔸 Kim Jørgensen (Permanent representation of the European Investment Bank (EIB)), 🔸 Raúl Martín-Ruiz (Ysios Capital), 🔸 Toon Digneffe (Takeda), and 🔸 Alexander Natz (EUCOPE - European Confederation of Pharmaceutical Entrepreneurs). 📈 At the start of the new European Commission's mandate, the conversation on #EUInnovation and #LifeSciences investment is more timely than ever. 🔗 Read the complete report here: https://lnkd.in/e46gFERR #LifeSciences #Innovation #EUCOPE #PharmaPackage #Investment

📝[𝐍𝐄𝐖 𝐑𝐄𝐏𝐎𝐑𝐓] 𝐁𝐢𝐨𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬: 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐬𝐚𝐧𝐝𝐛𝐨𝐱𝐞𝐬 𝐚𝐬 𝐚 𝐭𝐨𝐨𝐥 𝐭𝐨 𝐛𝐫𝐞𝐚𝐤 𝐝𝐨𝐰𝐧 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐛𝐚𝐫𝐫𝐢𝐞𝐫𝐬 🌱 This 2024 publication, authored by Professor, dr. juris Linda Nielsen for the Novo Nordisk Foundation, explores how innovative tools like regulatory sandboxes can accelerate innovation by enabling the development and scaling of Biosolutions. 𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐁𝐢𝐨𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬? Biosolutions are goods and services derived from combining biology and technology with the ambition of accelerating the green transition. Despite their transformative potential, current regulatory frameworks often stifle innovation, slowing the path to market and risking a European "brain drain" of talent and companies. 𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐬𝐚𝐧𝐝𝐛𝐨𝐱𝐞𝐬? Regulatory sandboxes are an attempt to remove barriers and increase the speed of the development of innovative solutions. Crucial elements are a structured context for testing, in a limited part of a sector or area, under supervision of a competent authority, and ensuring that appropriate safeguards are in place. The hope is that regulatory sandboxes can create interim solutions, which can help innovation to be tested, scale-up and come faster to market - in a soft, safe and supervised environment. The report outlines a vision for Europe to transition from “red tape” to a “red carpet” approach, positioning itself as a global leader in #Biosolutions #innovation. 👉Read the report here 🔗 https://shorturl.at/avGCB

Bolstering the U.S. bioeconomy: a Q&A with @RepAuchincloss. Jake Auchincloss is a co-sponsor of the #BiosecureAct, but he’s looking past decoupling the U.S. and Chinese biotech industries and is focusing on policies to enhance the competitiveness of the U.S. bioeconomy. In conversation with @SteveUsdin1

#EU #StrongerTogether 🇪🇺 💻👨🎓📥📤📈👨🎓💥 🔬🧩📈💚 🇪🇺 RT: EuropaBio - the European Association for Bioindustries "#Biotech on the spotlight 🩵🧬🩵🧬🩵🧬The European Innovation Council and SMEs Executive Agency (#EISMEA) placed #biotech as core #technology for Europe Platform in their latest 2025 #EIC Work Programme. EuropaBio - the European Association for Bioindustries welcomes the Programme as part of a long-term vision to set an ambitious and competitive European biotech ecosystem. An integrated approach from early research to access to the market is more than needed for biotech and biomanufacturing applications. EuropaBio looks towards the future EU #BiotechAct to complement these financing efforts and ensure the EU environment supports the development and deployment of biotech innovation. Published a few days ago, the Programme established a funding system to support innovative and resilient sectors advancing EU leader role in solving urgent global challenges. You can find the all document below ⬇️ https://lnkd.in/d5975htg #Science #Biotechnology #Bioeconomy #Prosperity #greeneconomy #environment #ecology #climatechange

Embracing the Future of European Industrial Policy I am delighted to read the recent Council conclusions on “A competitive European industry driving our green, digital and resilient future”, adopted on the initiative of the Belgian Presidency of the Council of the European Union. These conclusions lay the groundwork for a new European competitiveness deal and offer a strategic vision for the future of the EU's industrial policy. Driving Innovation and Competitiveness: Innovation stands at the heart of European competitiveness. The conclusions call for the identification of strategic priorities in the EU's industrial research and innovation policy, aiming to bridge the “innovation paradox” and facilitate the translation of knowledge into marketable products and services. Strengthening Business Environment and IP Framework: The conclusions explore avenues to boost private and public finance instruments. Moreover, the document underscores the need to establish the right framework conditions for industry success, including the protection of intellectual property (IP) and the facilitation of investment while safeguarding competition. Embracing Green and Digital Innovation: The document emphasizes the significance of the green and digital transition, presenting opportunities and challenges for companies and citizens alike. Our commitment to digital leadership in drug discovery and delivery, and climate neutrality serves as a cornerstone for building industrial leadership and fostering high-quality jobs. Merck Group stands ready to embrace the outlined principles and collaborate in building a competitive, innovative, and sustainable industrial landscape for a brighter future, including via ongoing revision of the EU General Pharmaceutical Legislation (#GPL). In order for pharmaceutical innovation to happen, I am convinced we firstly need the right environment in which we can be bold and innovate to address growing unmet medical needs, including in areas such as cancer. Secondly, we also stand ready to continue working closely with the Member States and other stakeholders, including patients, via different forums, to ensure equal access to medicines and strengthen security of supply. All these are correlated and cannot go one without the other, but as always innovation is the solution! https://lnkd.in/d8q3zhYa #EuropeanIndustrialPolicy #Innovation #Competitiveness #IntellectualProperty #Sustainability #AccesstoMedicines #SecurityofSupply